Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Research & Development (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Research & Development readings, the most recent being $13.3 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 62.13% to $13.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $50.1 million, a 104.95% increase, with the full-year FY2025 number at $50.1 million, up 104.95% from a year prior.
  • Research & Development hit $13.3 million in Q4 2025 for Avalo Therapeutics, down from $13.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $25.2 million in Q1 2021 to a low of $1.2 million in Q3 2023.
  • Median Research & Development over the past 5 years was $8.8 million (2022), compared with a mean of $9.0 million.
  • Biggest five-year swings in Research & Development: crashed 82.26% in 2023 and later surged 663.65% in 2024.
  • Avalo Therapeutics' Research & Development stood at $11.5 million in 2021, then plummeted by 46.38% to $6.2 million in 2022, then tumbled by 69.75% to $1.9 million in 2023, then soared by 338.3% to $8.2 million in 2024, then skyrocketed by 62.13% to $13.3 million in 2025.
  • The last three reported values for Research & Development were $13.3 million (Q4 2025), $13.6 million (Q3 2025), and $14.1 million (Q2 2025) per Business Quant data.